Aims: The present study was to evaluate the serum calcium level, phosphorus and 25 (OH) vitamin D subjects during HIV infection; precisely in patients living with HIV (PLHIV). Study Design: Prospective and experimental study, involving a cohort of blood samples from HIVnegative and positive subjects.

In 2019, the coronavirus pandemic broke out as a serious public health issue worldwide. In Côte d'Ivoire, the number of cases of COVID-19 has increased rapidly. The Severe Acute Respiratory Syndrome virus (SARS-CoV-2) binds to angiotensin converting enzyme 2 (ACE2) receptors in the respiratory tracts and enters the respiratory and alveolar cells of infected patients. Deficiency of fat-soluble vitamin D 3 is associated with respiratory distress syndrome and pulmonary fibrosis by activation of the renin-angiotensin system. In Côte d'Ivoire, very little research is being done on SARS-CoV-2 and vitamin D. The objective of this study was to assess the vitamin D status of people infected and suffering from COVID-19 in order to contribute to their medical treatment. The study involved 100 adults infected with SARS-CoV-2 (24 women and 76 men). After confirmation of the patient's SARS-CoV-2 status by RT-PCR, the 25 (OH) vitamin D assay was performed on the Cobas 6000 device and compared to control subjects, the non-COVID-19 positive. A significant decrease in 25-hydroxy vitamin D 3 concentrations (44 ± 1.29 nmole/L) was observed in patients infected with SARS-CoV-2, compared to control (78 ± 0.68 nmole/L) (p < 0.0001). The 25-hydroxy vitamin D 3 deficiency requires vitamin D supplementation in the management of hospitalized patients infected with SARS-CoV-2.

Background: Micronutrients play an important role in the human immune system. During HIV infection, the virus utilises the micronutrients of the body, for its replication causing metabolic disorders including phosphocalcic. Parathyroid hormone (PTH), vitamin D3 (25-hydroxyvitamin D3) and calcitonin are essential for the maintenance of phosphocalcic homeostasis and the proper functioning of the body. In Côte d'Ivoire, very few studies on HIV infection and the mechanism of phosphocalcic metabolism have been done. The purpose of this study was to determine the status of 25 (OH) D3 and parathyroid hormone in people living with HIV. Methodology: The study involved 326 adults (163 HIV-positive and 163 HIV-negative as control subjects). After confirmation by HIV serologic scanning result, CD4 count was performed by flow cytometry (Facs Calibur). Assays for 25 (OH) D3 and PTH were performed by HPLC and COBAS 6000 automated systems, respectively. Results: A decrease in mean values ​​of 25 (OH) D3 (16 ± 0.46 ng / mL) was observed in 50% of HIV-infected on ART and 87% of these patients presented a normal PTH level (28 ± 1.95 pg / mL). Deficiency of 25 (OH) D3 (20 ± 1.03 ng / mL) is higher in HIV-infected on ART who have a CD4 count < 200 cells / mL. Conclusion: Parathyroid hormone levels were normal in this study. Insufficiency or deficiency of 25-hydroxyvitamin D3 is more common in HIV-infected on ART with a CD4 count < 200 cells / mL. This decrease characterized the degree of immunodepression.

Background:A number of studies have highlighted the phosphocalcic balance disorder and posed the problem of the correlation between 25-hydroxyvitamin D 3 and parathyroid hormone in people living with HIV (PLHIV). However, few studies have been conducted on the link between antiretroviral therapy and the level of 25 (OH) D 3 during HIV infection. The objective of this study was to evaluate 25 (OH) D 3 and the parathyroid status in HIV-infected people taking antiretroviral treatment in Côte d'Ivoire.